Free

This is a FREE video. Register with us if you do not have a BIR account, before continuing to watch and claim your CPD.

Watch Now

  To see members' videos, become a member today!

Join Us

Back to Video List

PET-CT in brain tumor imaging 15 Jun 2019

In this webinar video, Dr Egesta Lopci explains the use of PET-CT in brain tumor imaging.

1 CPD credit.
Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.

Duration:39 mins


Speaker info

Egesta Lopci

Dr Lopci has graduated cum laude in Medicine and Surgery at the Alma Mater Studiorum, University of Bologna, Italy. At the same University she finished her specialization in Nuclear Medicine in 2011 and completed her PhD in Specialized Medical Sciences in 2016. From 2017 till 2019, Dr Lopci followed the EORTC Early Career Investigators (ECI) Leadership programme. Since 2011, Dr Lopci works at the Humanitas Research Hospital as Nuclear Medicine Consultant, directly involved in Clinical and Research activities in collaboration with other disciplines. She is an active member of several international organizations, such as AIEOP Hodgkin Lymphoma Interest Group, EANM Oncology Committee, SIOPEN NM Subcommittee, EORTC Imaging Group and Lung Cancer Group, UEMS/EBNM CME Accreditation Committee, and Chair of the EORTC IG Educational Subcommittee. Over the years, she has won different grants and over 10 awards and recognitions for her research activity in nuclear oncology. Dr. Lopci is author of 103 scientific papers, 4 books and 11 chapters on Nuclear Medicine discipline. Author of over 125 congress communications in the following scientific societies: EANM, SNMMI, AIMN, ESR, ESMO, ESTRO, EANO, RSNA, AUA, CAYAHL, IMIG. In 2017 she obtained the Italian national scientific qualification as Professor in Diagnostic Imaging and Radiotherapy. Her research interests include Clinical research on molecular imaging applications for nuclear oncology (brain, lung, pleura, prostate, liver cancer, lymphoma, neuroendocrine, sarcoma, etc., in adult and pediatric population), with particular interest on response assessment and immunotherapy.